GLPG2737 + Placebo

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Autosomal Dominant Polycystic Kidney Disease

Conditions

Autosomal Dominant Polycystic Kidney Disease

Trial Timeline

Nov 10, 2020 → Apr 4, 2023

NCT ID

NCT04578548

About GLPG2737 + Placebo

GLPG2737 + Placebo is a phase 2 stage product being developed by Galapagos for Autosomal Dominant Polycystic Kidney Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT04578548. Target conditions include Autosomal Dominant Polycystic Kidney Disease.

What happened to similar drugs?

1 of 5 similar drugs in Autosomal Dominant Polycystic Kidney Disease were approved

Approved (1) Terminated (2) Active (2)

✅Placebo + EverolimusNovartisApproved

🔄Everolimus + Calcineurin inhibitors maintenanceNovartisPhase 3

❌Bardoxolone methyl oral capsule + Placebo oral capsuleBiogenPhase 3

🔄Lanreotide + salineIpsenPhase 3

❌Lixivaptan + PlaceboCentessa PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04578548	Phase 2	Terminated	Nov 10, 2020	Apr 4, 2023	Autosomal Dominant Polycystic Kidney Disease
NCT03474042	Phase 2	Completed	Nov 29, 2017	Apr 10, 2018	Cystic Fibrosis

Competing Products

19 competing products in Autosomal Dominant Polycystic Kidney Disease

See all competitors

Product	Company	Stage	Hype Score
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	42
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B	AstraZeneca	Phase 1	36
Placebo + Everolimus	Novartis	Approved	43
Octreotide + Placebo	Novartis	Phase 2/3	38
Everolimus + Calcineurin inhibitors maintenance	Novartis	Phase 3	40
Bosutinib + Bosutinib + Placebo	Pfizer	Phase 2	35
VX-407	Vertex Pharmaceuticals	Phase 2	42
VX-407 + LNG/EE + NGM/EE + NET/EE + DRSP/EE	Vertex Pharmaceuticals	Phase 1	33
VX-407 + Placebo + Midazolam + VX-407	Vertex Pharmaceuticals	Phase 1	29
VX-407 + Placebo	Vertex Pharmaceuticals	Phase 1	33
Tesevatinib	Sanofi	Phase 1/2	32
Tesevatinib + Placebo	Sanofi	Phase 2	35
Venglustat + Placebo	Sanofi	Phase 2/3	30
Bardoxolone methyl oral capsule + Placebo oral capsule	Biogen	Phase 3	29
Lanreotide + saline	Ipsen	Phase 3	37
KB105	Krystal Biotech	Phase 2	28
KB105	Krystal Biotech	Phase 1/2	25
Lixivaptan + Placebo	Centessa Pharmaceuticals	Phase 3	29
QR-1123	ProQR	Phase 1/2	26